Annovis Bio, Inc. (ANVS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-10

Key Insights

Annovis Bio has entered into an underwritten registered direct offering, raising approximately $10 million in gross proceeds to fund the continued clinical development of its lead compound Buntanetap for Alzheimer's disease.
The offering includes the issuance of 5,263,156 shares of common stock and 5,263,156 accompanying common stock warrants, with an exercise price of $2.50 per share and a 5.5-year term.
The company plans to use the net proceeds from the offering for the Buntanetap clinical development and for general corporate purposes.

Want the newest filings?

This analysis covers the filing from 2026-04-10. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-25

Annovis Bio's Chief Financial Officer, Mark Guerin, has departed the company effective March 23, 2026, but the departure was not due to any disagreement with the company.
The company's CEO, Maria Maccecchini, will serve as Acting Chief Financial Officer until a replacement is identified.
The departure of the CFO could signal potential changes in the company's financial leadership and operations, which investors should closely monitor.

Filed: 2026-03-16

Annovis Bio, Inc. reported earnings for the year ended December 31, 2025, which may provide investors with insights into the company's financial performance and future outlook.
The press release issued on March 16, 2026 could indicate a material update or development in the company's business that investors should be aware of.
Investors may want to closely review the financial results and any accompanying commentary from management to assess the company's overall performance and prospects.

Filed: 2026-02-12

Annovis Bio, Inc. filed an 8-K report on February 12, 2026, providing a press release as the only disclosed information.
As an emerging growth company, Annovis Bio has the option to use the extended transition period for complying with new or revised financial accounting standards.
The 8-K filing does not provide any details on material agreements, leadership changes, or financial performance, limiting the insight into the company's current status and outlook.

Filed: 2026-01-28

Annovis Bio will be hosting a webinar on January 28, 2026, which could provide updates on the company's business and potentially move the stock price.
The filing does not provide any financial or operational updates, suggesting the webinar may be the primary focus of this 8-K filing.
Investors should closely monitor the content and tone of the webinar presentation to assess the company's current state and future prospects.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.